Data-Gouv-ML/pcri-informations-sur-les-projets-laureats huggingface dataset:
European Project on Mendelian Forms of Parkinson’s Disease (MEFOPA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Germany,Greece,Sweden,Denmark,Portugal,United Kingdom,Switzerland,France,Belgium,United Kingdom,France,Spain,Italy,Germany,Hungary,Netherlands,United Kingdom,Norway,United Arab Emirates,Türkiye,Spain
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-04-01
End date: 2013-09-30
Duration (months): 42.0
Total project cost (EUR): 8053959.33
EU funding (EUR): 5759468.0
Participants: 23
Project status: CLOSED

The Collaborative Project on Mendelian Forms of Parkinson’s Disease (MEFOPA) will bring together the major groups in Europe with a track-record in basic and clinical research on rare Mendelian forms of Parkinson’s disease (PD) in order to identify and validate relevant disease-related molecular pathways, drug-targets and biomarkers for disease susceptibility and progression.. Over the last years it has become increasingly clear that progress in the understanding of the molecular basis of PD, the second most common neurodegenerative disorder, and hence the chance to develop effective disease-modifying treatments, will most likely be brought about by focusing on the rare variants of the disease with known genetic defects. The groups forming the MEFOPA-consortium will therefore analyze the molecular pathways underlying inherited forms of PD with autosomal-dominant and autosomal-recessive inheritance in an integrative way, using cellular and animal models and cutting-edge technology. These two subprojects will provide targets for novel, disease-modifying treatment strategies. In a third subproject, a European registry and biobank for patients with rare Mendelian forms of PD will be established. Body fluids will be collected and systematically analyzed by unbiased proteomic techniques as well as by focussed analysis of candidate proteins, and ex vivo cellular models will be generated, in order to allow validation of disease-related alterations detected in the models analyzed in subprojects 1 and 2. Through this integrated, translational approach combining basic and clinical research groups, the project aims to achieve measurable progress in defining the relevant targets and readouts for disease-modifying therapies and will set the stage for rationally designed drug trials in carefully selected groups of patients and even presymptomatic mutation carriers.

Keywords: brain research,translational research,rare diseases
Impact of Specific Antibiotic Therapies on the prevalence of hUman host ResistaNt bacteria (SATURN)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Switzerland,Poland,Israel,Belgium,Italy,Netherlands,France,Spain,Germany,Serbia,Netherlands,Germany,Romania
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-12-31
Duration (months): 60.0
Total project cost (EUR): 7821538.34
EU funding (EUR): 5999436.0
Participants: 16
Project status: CLOSED

Many results drawn from previous studies of the effect of antibiotic use on emergence, selection and spread of antimicrobial resistance (AMR) have lacked a holistic view combining all aspects into one study. The SATURN project aims to study the impact of antibiotic exposure on AMR with a multidisciplinary approach that bridges molecular, epidemiological, clinical and pharmacological research. Two types of clinical studies will be conducted: First, a randomized trial will be performed to resolve an issue of high controversy (antibiotic cycling vs. mixing). Second, 3 observational studies will be conducted to rigorously study issues surrounding the effect of antibiotic use on AMR that are not easily assessable through randomized trials. These clinical studies will serve as a platform to 2 complementary workpackages (microbiology &amp;amp; pharmacology) that will perform important investigations relevant to this call. The work package focusing on molecular studies will generate new evidence about the changes effected by antibiotic therapy on commensal organisms or opportunistic pathogens in the oropharyngeal, nasal and gastro-intestinal flora and study AMR mechanisms and the dissemination of successful clones of fluoroquinolone-resistant, carbapenem-resistant or extended-spectrum beta-lactamase harboring Gram-negative bacteria, MRSA and fluoroquinolone-resistant viridans streptococci. The purpose of the pharmacodynamic study is to model the relationships between antibiotic exposure and AMR emergence over time for various classes of agents. In summary, the overarching rationale of SATURN is to improve methodological standards and conduct research that will help to better understand the impact of antibiotic use on acquisition, selection and transmission of AMR in different environments, by combining analyses of molecular, individual patient-level and ecologic data. The anticipated results may guide clinical and policy decisions to ultimately reduce the burden of AMR in Europe.

Keywords: antimicrobial resistance - antibiotic resistant bacteria - pharmacokinetics -pharmacodynamics - microbiology - bacterial genetics - epidemiology - therapeutic drug use -
Access to Pharmaceuticals (ATP)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: United Kingdom,Switzerland,South Africa,Korea, Republic of,Brazil
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-10-01
End date: 2013-03-31
Duration (months): 42.0
Total project cost (EUR): 2278506.31
EU funding (EUR): 1754774.0
Participants: 5
Project status: CLOSED

Access to Pharmaceuticals Equitable access to pharmaceuticals, particularly for developing countries is an essential human right. Various complex impediments hinder access, which is the subject of ongoing multidisciplinary studies. Intellectual Property and product development are two issues that can be used as tools to address the problem of access, particularly to make patented drugs more affordable and accessible. This proposal addresses three ways of accomplishing this. The first is how academic licensing practices under socially responsible stewardship can ensure that future drugs that have resulted from inventive activity in academia will be available at low cost with improved access in the future. Secondly we will research thoroughly how existing public-private or product-development partnerships are addressing the issue of altruistic development of drugs for relatively neglected populations with unmet health needs and the lessons they have for future drug development. Lastly it addresses the current state and future improvements in compulsory licensing legislative instruments to enable access through generic manufacture of patented drugs. The three routes to access have several significant aspects of overlap which provide for complementary approaches and solutions to access.

Keywords: pharmaceuticals,access to medicines,developing countries,licensing,compulsory licensing,product development partnerships
Regenerating Bone defects using New biomedical Engineering approaches (REBORNE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: France,France,France,Italy,Belgium,Spain,Spain,Romania,France,Germany,Germany,Norway,Netherlands,Germany
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2015-06-30
Duration (months): 66.0
Total project cost (EUR): 15472075.44
EU funding (EUR): 11935340.0
Participants: 24
Project status: CLOSED

Bone is among the most frequently transplanted tissue with about 1 million procedures annually in Europe. The worldwide market of bone replacement materials is currently estimated at 5 billion € with a 10% annual growth. Despite their considerable disadvantages, including the risk of disease transfer and immunologic rejection, limited supply of bone, costs and complications, allografts and autografts account for more than 80% of total graft volume. Significant growth opportunities exist for synthetic bone grafts in association with mesenchymal stem cells from autologous or allogenic sources as alternatives to biological bone grafts in orthopaedic and maxillofacial surgery. The objectives of REBORNE is to perform clinical trials using advanced biomaterials and cells triggering bone healing in patients. In order to reach this goal, five phase II clinical studies with 20 patients are proposed in 12 clinical centres spread in 8 European countries. Three orthopaedic trials concerning the treatment of long bone fractures and osteonecrosis of the femoral head in adults or children will be conducted using bioceramics, hydrogel for percuteneous injection and stem cells from autologous or allogenic sources. Clinical research will also concern maxillofacial surgery with bone augmentation prior to dental implants and the reconstruction of cleft palates in children. The safety and efficacy of the new therapies will be assessed clinically using X-rays, CT scans and MRI as well as histology of biopsies. These ambitious clinical targets will require research and development efforts from a large consortium of top world class laboratories, SMEs manufacturing biomaterials, GMP-cell producing facilities and surgeons in hospitals as well as the consideration of ethical and regulatory issues. It is expected that REBORNE will expand the competitiveness of Europe through the patenting of new CE-marked bioproducts in the field of regenerative medicine.

Keywords: regenerative medicine,bone tissue engineering,biomaterials,stem cells,orthopaedic,maxillofacial
Light-based functional in vivo monitoring of diseases related enzymes (LIVIMODE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Biotechnology, generic tools and medical technologies for human health
Action type: Collaborative project
Countries involved: Slovenia,Switzerland,Spain,United Kingdom,Germany,France,Germany,France,Germany,Spain,United Kingdom
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2009-11-01
End date: 2013-04-30
Duration (months): 42.0
Total project cost (EUR): 6867435.87
EU funding (EUR): 4850785.0
Participants: 11
Project status: CLOSED

LIVIMODE aims to develop specific tools for non invasive in vivo imaging of disease related molecular events. Such tools are of high relevance for disease detection, staging, developing animal models of human disease, and evaluating novel therapies. We propose to use optical imaging, which is optimally suited for this task as it provides excellent sensitivity and allows visualizing molecular events via a fluorescent signal. While optical imaging technology has rapidly evolved over the last years, the availability of SMART (activatable) imaging agents that change their fluorescence properties upon disease related events, remains a critical gap. The LIVIMODE project proposes to combine expertises in medicinal chemistry, pharmacology and imaging in a conceptually new approach in designing SMART agents. In particular, we will (i) translate established strategies in medicinal/pharmaceutical chemistry to design highly selective SMART probes and (ii) optimize the cell/tissue specificity of probes integrating concepts from polymer and protein based targeted drug delivery. We will generate a toolset of highly selective targeted SMART probes for at least 10 disease-relevant proteases. The selection of target proteases is based on their relevance in disease processes that cannot yet be monitored with non invasive technology. These include (i) the development of tumor microenvironment as a critical factor in oncogenesis, (ii) tumor hypoxia and angiogenesis, and (iii) inflammatory and degenerative processes in osteoarthritis. LIVIMODE has established animal models for these conditions and will use in vivo optical imaging to evaluate the novel SMART probes as tools for monitoring disease progression and drug efficacy. This will enhance our knowledge of disease mechanisms and our ability to rapidly characterize drug candidates for in vivo efficacy (proof-of-efficacy). Selected SMART probes will be optimized to assess their potential as clinical diagnostics.

Keywords: smart imaging activatable agents,in vivo disease imaging,early diagnosis,cancer,osteoarthritis,protease
Prevention of Hospital Infections by Intervention and Training (PROHIBIT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Optimising the delivery of healthcare to European citizens
Action type: Collaborative project
Countries involved: Switzerland,Netherlands,Germany,Germany,France,Hungary,United Kingdom,Switzerland,Poland
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-01-01
End date: 2014-06-30
Duration (months): 54.0
Total project cost (EUR): 3887004.82
EU funding (EUR): 2999934.0
Participants: 9
Project status: CLOSED

The aim of PROHIBIT is to understand existing guidelines and practices to prevent healthcare associated infections (HAI) in European hospitals, identify factors that enable and prevent compliance with best practices, and test the effectiveness of interventions of known efficacy. The project will employ a mixed-methods approach combining the strengths of qualitative research, survey methods, observational and experimental designs. First, we will systematically review current guidelines on prevention of the most common HAIs within the EU, as well as schemes for surveillance and public reporting. Next, we will conduct a large-scale survey of what is actually being done in European hospitals, determining factors, and how these relate to bloodstream infection rates. The project will then focus on catheter-related bloodstream infection (CRBSI), a highly transmissible and reliably measured HAI, in a selected sample of European hospitals. In-depth interviews of healthcare staff and direct observation will be used to measure compliance with key prevention practices. A randomized effectiveness trial using a stepped wedge design will be conducted in intensive care units to determine the uptake and impact of 2 interventions (WHO hand hygiene protocol and so-called catheter bundle) on CRBSI as well as clinical and utilization outcomes. The information will be synthesized to develop recommendations for the EU, policy makers, managers and medical professionals to prevent HAI. Dissemination will include instructional workshops and on-line training materials.

Keywords: patient safety,healthcare-associated infection,catheter-related blood stream infection,hand hygiene,hospital,guidelines,effectiveness
A systems biology approach to dissect cilia function and its disruption in human genetic disease (SYSCILIA)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,Germany,United States,Germany,Germany,Italy,Netherlands,United Kingdom,United Kingdom,Ireland,France,Germany,Germany,Germany,France,United Kingdom
Call:  (FP7-HEALTH-2009-two-stage, 2009)
Start date: 2010-06-01
End date: 2015-05-31
Duration (months): 60.0
Total project cost (EUR): 14939311.2
EU funding (EUR): 11069083.0
Participants: 17
Project status: CLOSED

AIM: To identify the molecular mechanisms characterizing cilium function, and the discrete perturbations associated with dysfunction caused by mutations in inherited ciliopathies, applying a systems biology approach. BACKGROUND: Cilia are microtubule-based, centriole-derived projections from the cell surface. They transduce extracellular signals and regulate key processes in which signals of the extracellular environment are translated into a cellular response, such as cell cycle control, Wnt signalling, Shh signalling and planar cell polarity. Disruption of cilium-based processes by mutations can cause very severe disorders. Many of these ciliopathies have overlapping phenotypes. There is evidence, that ciliary proteins are organized in cell/context specific complexes and/or in shared regulatory circuits in cilia of affected tissues. Yet, knowledge of the composition, wiring, dynamics and associated signaling pathways of the corresponding molecular building blocks and associated protein networks remains very limited. APPROACH: We propose here that ciliopathies can be considered systemically as specific perturbations in a versatile dynamically regulated multifunctional molecular machine. Mainly based on the comprehensive description of the ciliary interactome, quantitative functional assays as well as human genetic data derived from ciliopathy patients, we will generate a comprehensive stream of content-rich quantitative data towards systemic analysis of ciliar function. These data will be used to generate and validate discrete models that describe functional modules and regulatory circuits in the ciliome as well as predicting biological context specific features of cilia as well as perturbations leading to ciliopathies. This will enable us to 1) understand the systemic features of discrete ciliary functions, 2) scrutinize the molecular disease mechanisms of different overlapping ciliopathies, and 3) develop therapeutic strategies towards improved treatment.

Keywords: systems biology cilia ciliopathies protein networks bioinformatics
Paediatric European Risperidone Studies (PERS)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Netherlands,Netherlands,Germany,United Kingdom,United Kingdom,France,Spain,Spain,Italy,Belgium,Italy,Germany,United Kingdom,Germany,Netherlands
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-05-01
End date: 2015-04-30
Duration (months): 60.0
Total project cost (EUR): 7360763.2
EU funding (EUR): 5600000.0
Participants: 21
Project status: CLOSED

Second-generation antipsychotics are increasingly being prescribed to children and adolescents. Their use, however, is mostly off-label, and adequate and sufficient data about efficacy and particular safety are lacking. This proposal focuses on two indications, the use of risperidone in children and adolescents with conduct disorder who are not mentally retarded, and the use of risperidone in adolescents with schizophrenia. The objectives are to 1) perform a series of clinical studies that will provide sufficient information for a Paediatric Use Marketing Authorisation to be obtained for these indications; 2) address scientific questions about the moderating and/or mediating factors of the efficacy and safety of risperidone in children and adolescents, and 3) disseminate the knowledge acquired by the proposed studies to medical and mental health professionals, to patients and their families and society in general.

Keywords: second-generation antipsychotics,risperidone,conduct disorder,schizophrenia,child,adolescent,paediatric use marketing authorisation (puma)
health-economic modelling of PREvention strategies for Hpv-related Diseases in European CounTries (PREHDICT)

Framework: FP7 — Cooperation
Programme: Health
Destination: Other Actions across the Health Theme
Action type: Collaborative project
Countries involved: Netherlands,Spain,Italy,Sweden,Finland,Belgium,United Kingdom,France,Sweden
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-05-01
End date: 2013-04-30
Duration (months): 36.0
Total project cost (EUR): 3774909.6
EU funding (EUR): 2963532.0
Participants: 13
Project status: CLOSED

The goals of the PREHDICT study are to determine prerequisites and strategies for vaccination in European countries and to predict the impact of vaccination on screening programmes. To achieve these goals, a multiple HPV type transmission model will be built to describe the type-specific incidence and clearance of HPV infections. This model will be linked to an individual-based simulation model used for modelling the impact of screening. For HPV-related diseases other than cervical cancer and genital warts, Markov models will be developed after critical review of the role of HPV. In the PREHDICT study, country-specific cost-effectiveness analyses will be performed for the vaccination and include determination of the vaccination age, the number of doses, the vaccination population, and the optimal catch-up vaccination age. Furthermore, the impact of vaccination on screening programmes will be assessed. This involves determination of the screening technology, screening frequency, and follow-up management of test-positive women. Special attention will be given to screening attendance and its relation to vaccination attendance. To have models with strong empirical support, the PREHDICT team will collect the most updated data on HPV infection, HPV-related disease, life-style factors, and demographics. Furthermore, HPV-type specific analyses will be performed on the outcomes of a vaccination trial, 3 large screening trials, and one self-sampling trial for screening non-attenders. By meta-analytical techniques, results will be pooled. The costs involved in the calculations will include the costs of organizing, running, and monitoring a vaccination and/or screening programme. The results of the PREHDICT study will be published in international peer-reviewed journals, posted on the WHO HPV information centre website and will also be systematically disseminated to all major stakeholders, in particular to decision makers at European, national and sub-national levels.

Keywords: vaccination,screening,hpv-related disease,transmission model,individual-based model,cost-effectivenes
OPtimization of Treatment and Management of Schizophrenia in Europe (OPTiMiSE) (OPTIMISE)

Framework: FP7 — Cooperation
Programme: Health
Destination: Translating research for human health
Action type: Collaborative project
Countries involved: Netherlands,United Kingdom,France,Germany,Germany,Denmark,Spain,Austria,Belgium,Israel,Poland,Italy,Germany,Czechia,Germany,France,Germany,Switzerland,Romania,Bulgaria
Call:  (FP7-HEALTH-2009-single-stage, 2009)
Start date: 2010-02-01
End date: 2016-07-31
Duration (months): 78.0
Total project cost (EUR): 14900190.31
EU funding (EUR): 11187685.42
Participants: 23
Project status: CLOSED

OPTiMiSE (OPtimization of Treatment and Management of Schizophrenia in Europe) will focus on two goals: optimising current treatments in Schizophrenia and explore novel therapeutic options for schizophrenia. The project intends to both address basic, but so far unanswered, questions in the treatment of schizophrenia and develop new and experimental interventions. It is expected that the project will lead to evidence that is directly applicable to treatment guidelines, will explore the development of novel treatments and will identify potential mechanisms for new drug development. To achieve these goals we have assembled a European team of experts that is second to none in the world. Together we will pursue the following objectives: -To use MRI to optimise treatment outcome and to facilitate prediction of response to treatment; - To provide a rational basis for antipsychotic choices in the treatment of first episode schizophrenia or schizophreniform disorder; - To improve functional outcome and reduce drug discontinuation by means of psychosocial interventions. - To explore the potential of cannabidiol CBD, a modulator of endocannabinoid functioning, as an alternative to D2 based antipsychotics - To validate a new approach to improve cognitive performance in patients with cognitive deficits on the basis of their genetic make up; - To use theoretically driven neurochemical imaging (MRS) and empirically driven genetic/genomic markers as predictors of response to treatment.

Keywords: schizophrenia treatment,mri,psycho-educational intervention,cannabidiol,l-dopa,neurochemical predictors,genomics,metabolomics,proteomics